NCT05241522View on ClinicalTrials.gov

Dosimetry of Tc-99m-Tilmanocept

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

December 31, 2024

Conditions
Diabetic Kidney Disease
Interventions
DIAGNOSTIC_TEST

Tc-99m-Tilmanocept

Administration of 3 different doses of Tc-99m-Tilmanocept prior to SPECT-CT imaging of the kidney in order to determine the safety and efficacy of tilmanocept imaging for differentiating diabetic kidney disease from other causes of kidney disease.

Trial Locations (1)

92103

RECRUITING

UC San Diego Medical Center, San Diego

All Listed Sponsors
lead

University of California, San Diego

OTHER

NCT05241522 - Dosimetry of Tc-99m-Tilmanocept | Biotech Hunter | Biotech Hunter